Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial

Abstract We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important contributor to the innate immune system and can also activate the coagulation system. High C5a le...

Descrición completa

Detalles Bibliográficos

Principais autores:	Endry H. T. Lim, Alexander P. J. Vlaar, Lieuwe D. J. Bos, Lonneke A. van Vught, Anita M. Tuip-de Boer, Romein W. G. Dujardin, Maria Habel, Zhongli Xu, Matthijs C. Brouwer, Diederik van de Beek, Sanne de Bruin, the Amsterdam UMC COVID-19 Biobank Investigators
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2022-12-01
Series:	Respiratory Research
Assuntos:	SARS-CoV-2 COVID-19 Complement Complement inhibition Vilobelimab C5a
Acceso en liña:	https://doi.org/10.1186/s12931-022-02278-1
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!